Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer
# Background Bacillus Calmette-Guérin (BCG) can reduce recurrence and delay progression among patients with high-risk non–muscle invasive bladder cancer (NMIBC), but is associated with a substantial emotional, physical, and social burden. # Objectives This study evaluated the adequacy of first-line...
Saved in:
| Main Authors: | Franklin D. Gaylis, Bruno Emond, Ameur M. Manceur, Anabelle Tardif-Samson, Laura Morrison, Dominic Pilon, Patrick Lefebvre, Lorie A. Ellis, Hiremagalur Balaji, Andrea Ireland |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2024-10-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.124208 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pneumonitis secondary to intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy
by: Komeil Alattar, MBBS, PGCert, et al.
Published: (2025-09-01) -
Safety profiles of intravesical Bacillus Calmette-Guerin in bladder cancer
by: Yun Peng, et al.
Published: (2024-12-01) -
Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin
by: Sayed Ab. Reshad Ghafouri, et al.
Published: (2018-01-01) -
Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
by: Dong Ha Kim, et al.
Published: (2024-12-01) -
Afebrile tuberculous prostatic abscess with rectal fistula after intravesical Bacillus Calmette‐Guérin immunotherapy
by: Tatsuhiro Sawada, et al.
Published: (2025-01-01)